Dombrowski M P, Brown C L, Berry S M
Department of Obstetrics and Gynecology, Wayne State University/Hutzel Hospital, Detroit, MI 48201, USA.
J Matern Fetal Med. 1996 Nov-Dec;5(6):310-3. doi: 10.1002/(SICI)1520-6661(199611/12)5:6<310::AID-MFM3>3.0.CO;2-S.
Although inhaled corticosteroids have been recommended, there are no published reports of triamcinolone acetonide therapy for asthma during pregnancy. The objective of this study was to report our experience with triamcinolone acetonide during pregnancy. This was a retrospective cohort study in a tertiary care urban hospital. We compared birth weights and the proportion of subjects hospitalized for asthma exacerbations among pregnant women receiving inhaled triamcinolone acetonide, inhaled beclomethasone dipropionate, and oral theophylline. The mean triamcinolone acetonide group (n = 15) birth weight was 502 g more than the beclomethasone group (n = 14) and 316 g more than the theophylline group (n = 25); however, these differences were not statistically significantly. Fewer patients treated with triamcinolone acetonide (n = 5, 33%) required hospital admissions for asthma exacerbations compared to those treated with beclomethasone (n = 11, 79%; P < 0.05) but not theophylline (n = 7, 28%; P = NS). Our preliminary data suggest that triamcinolone acetonide appears to be at least as efficacious for the treatment of asthma during pregnancy as is beclomethasone. These results should be confirmed by a clinical trial to further evaluate the safety and efficacy of inhaled triamcinolone acetonide during pregnancy.
尽管吸入性糖皮质激素已被推荐使用，但关于妊娠期间使用曲安奈德治疗哮喘的报道尚未见发表。本研究的目的是报告我们在妊娠期间使用曲安奈德的经验。这是一项在城市三级医疗医院进行的回顾性队列研究。我们比较了接受吸入性曲安奈德、吸入性二丙酸倍氯米松和口服茶碱的孕妇的出生体重以及因哮喘加重而住院的受试者比例。曲安奈德组（n = 15）的平均出生体重比倍氯米松组（n = 14）重502克，比茶碱组（n = 25）重316克；然而，这些差异无统计学意义。与接受倍氯米松治疗的患者（n = 11，79%；P < 0.05）相比，接受曲安奈德治疗的患者（n = 5，33%）因哮喘加重需要住院治疗的人数较少，但与接受茶碱治疗的患者（n = 7，28%；P = 无统计学意义）相比无差异。我们的初步数据表明，曲安奈德在妊娠期间治疗哮喘的效果似乎至少与倍氯米松一样有效。这些结果应通过临床试验加以证实，以进一步评估吸入性曲安奈德在妊娠期间的安全性和有效性。
